History of the cholesterol hypothesis in Britain

QJM: An International Journal of Medicine

Volumn 102, Issue 6, 2009, Pages 436-438

  Grimes, David S ^a  

^a ROYAL BLACKBURN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; EZETIMIBE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN; PRAVASTATIN;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; HUMAN; ISCHEMIC HEART DISEASE; LETTER; MEDICAL RESEARCH; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT RESPONSE; UNITED KINGDOM;

EID: 67749108145     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcp029     Document Type: Letter

References (24)

1. Thompson GR. History of the cholesterol hypothesis in Britain. QJM 2009; 102:81-6.
2. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality: Implications from a cohort of 361,662 men. Lancet 1986; 328:933-6.
3. Rose G, Shipley M. Plasma cholesterol concentration and death from coronary heart disease: 10 year results of the Whitehall study. BMJ 1986; 293:306-7.
4. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA 1987; 257:2176-80.
5. Forette B, Tortrat D, Wolmark Y. Cholesterol as risk factor for mortality in elderly women. Lancet 1989; 333:868-70.
6. Krumholtz HM, Seeman TE, Merrill SS, Mendes de Leon CF, Vaccarino V, Silverman DI, et al. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: A cohort study. Lancet 2001; 358:351-5.
7. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total cholesterol and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97 2007-11.
8. Scandinavian Simvastatin Survival Study Group. Randomised controlled trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-9.
9. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995; 333:1301-7.
10. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the west of Scotland coronary prevention study (WOSCOPS). Circulation 1998; 97 1440-5.
11. Freeman DJ, Norrie J, Sattar N, Neely DG, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes mellitus; evidence for a protective treatment effect in the west of Scotland coronary prevention study. Circulation 2001; 103:357-62.
12. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Xiu-Ming-Wang, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333:621-7.
13. Katznelson S, Wilkinson AH, Kobashigawa JA, Wang XM, Chia D, Ozawa M, et al. The effect of pravastatin on acute rejection after kidney transplantation - a pilot study. Transplantation 1996; 61 1469-74.
14. Strandberg TE, Pyörälä K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004; 364:771-7.
15. Poytner JN, Gruber SB, Higgins PDR, Almog R, Bonner JD, Rennert HS, et al. Statins and risk of colorectal cancer. N Engl J Med 2005; 352:2184-92.
16. Thomsen RW, Riis A, Kornum JB, Kornum JB, Chrsitensen S, Johnsen SP, et al. Preadmission use of statins and outcomes after hospitalization with pneumonia. Arch Intern Med 2008; 168:2081-7.
17. Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone-mineral density in postmenopausal women. Lancet 2000; 355:2218-19.
18. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakova O, Ford I, et al. Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004; 363:2015-21.
19. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, MarkovicPlese S, et al. Oral simvastatin in relapsing-remitting multiple sclerosis. Lancet 2004; 363:1607-8.
20. Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: A populationbased cohort analysis. Lancet 2006; 367:413-18.
21. Katznelson S, Wang XM, Chia D, Ozawa M, Zhong HP, Hirata M, et al. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro. J Heart Lung Transplant 1998; 17:335-40.
22. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996; 348:1079-82.
23. Oliver MF. Statins prevent coronary heart disease. Lancet 1995; 346:1378-9.
24. Kastelstein JJP, Akdim F, Stroes ESG, Zwinderman AH, Bots ML, Stalenhoef AFM, et al. Simvastatin with or without ezetimibe in familial hypercholesterolaemia. N Engl J Med 2008; 358:1431-43.